Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Allogene pens $309mm deal with Notch, gaining equity stake and global rights to allogenic therapies for hematologic cancers

Executive Summary

Allogene Therapeutics Inc. and Notch Therapeutics (a 2018 start-up) agreed to jointly R&D induced pluripotent stem cell (iPSC)-derived allogeneic therapies for hematologic cancer indications, including non-Hodgkin lymphoma, leukemia, and multiple myeloma.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • R+D and Marketing-Licensing
    • Intra-Biotech Deal

Related Companies